Eton Pharmaceuticals (ETON) vs Zymeworks (ZYME)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Eton Pharmaceuticals (ETON) has outperformed Zymeworks (ZYME) over the past year, gaining 269.7% versus a gain of 8.8%. Over five years, ETON leads with a +1341.9% price change compared with +34.1% for ZYME. Zymeworks is the larger company by market cap ($1.81 billion vs $1.76 billion), about 1.0 times the size, while Eton Pharmaceuticals is growing revenue faster (+104.9% vs +38.9%).
On valuation, Eton Pharmaceuticals trades at a lower forward P/E (18.4x vs 55.0x for Zymeworks). Eton Pharmaceuticals converts more of its revenue into profit, with a net margin of -5.8% versus -76.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ETON | ZYME |
|---|---|---|
| Share price | $60.85 | $26.14 |
| Market cap | $1.76B | $1.81B |
| 1-day change | -0.83% | -2.68% |
| YTD return | +259.85% | -0.72% |
| 1-year return | +269.68% | +8.83% |
| 5-year return | +1341.94% | +34.05% |
| P/E ratio (TTM) | 39.51 | 49.32 |
| Forward P/E | 18.41 | 54.95 |
| EPS (TTM) | $1.54 | $0.53 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $79.95M | $105.97M |
| Revenue growth (YoY) | +104.94% | +38.87% |
| Net income (latest FY) | $-4.60M | $-81.13M |
| Gross margin | 53.46% | — |
| Operating margin | -1.06% | -87.34% |
| Net margin | -5.75% | -76.56% |
| 52-week high | $70.64 | $31.97 |
| 52-week low | $14.27 | $21.52 |
| Distance from 52-week high | -13.86% | -18.24% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +32.70% | +65.61% |
| Average volume | 570.79K | 1.09M |
| Shares outstanding | 28.84M | 68.70M |
| Employees | 44 | 279 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ETON has outperformed ZYME by 260.9 percentage points over the past year.
- Eton Pharmaceuticals is more profitable, keeping -5.8 cents of every revenue dollar as net income versus -76.6 cents for Zymeworks.
- Eton Pharmaceuticals grew revenue faster in its latest fiscal year (+104.94% vs +38.87%).
About Eton Pharmaceuticals
ETON stock →Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1.
Health Care · Biotechnology: Pharmaceutical Preparations · 44 employees
About Zymeworks
ZYME stock →Zymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases. The company's platforms include Azymetric multispecific antibody platform; Drug Conjugate platform that includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies; and ProTECT, a tumor-specific immune co-stimulation platform.
Health Care · Biotechnology: Pharmaceutical Preparations · 279 employees
ETON vs ZYME FAQ
Which is bigger, Eton Pharmaceuticals or Zymeworks?
Zymeworks (ZYME) is larger, with a market capitalization of $1.81B compared with $1.76B for Eton Pharmaceuticals (ETON).
Which stock has performed better over the past year, ETON or ZYME?
ETON returned +269.68% over the past 12 months, compared with +8.83% for ZYME (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, ETON or ZYME?
ETON has the lower trailing P/E at 39.5, versus 49.3 for ZYME. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Eton Pharmaceuticals and Zymeworks in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.